Global Hepatic Encephalopathy Market

Hepatic Encephalopathy Comprehensive Study by Application (Acute Liver Failure, Portal Systemic Bypass Without Liver Disease, Liver Cirrhosis), End users (Hospitals, Research Institutes, Clinics & Surgical centers, Others), Type (Type A, Type B, Type C), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Disease Severity (Covert Hepatic Encephalopathy (CHE), Overt Hepatic Encephalopathy (OHE)), Drug Class (Antibiotics, Laxatives, Others) Players and Region - Global Market Outlook to 2029

Hepatic Encephalopathy Market by XX Submarkets | Forecast Years 2024-2029 | CAGR: 6.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Hepatic Encephalopathy Market Scope
According to the Center for Disease Control and Prevention (CDC), in 2017, around 4.5 million adults were diagnosed with liver disease in the United States. Moreover, the number of deaths due to chronic liver disease and cirrhosis accounted for 40,545 in 2017. Hepatic encephalopathy (HE) is a disorder that arises due to accumulated toxins in the brain which leads to liver diseases. It is a syndrome that occurs in patients with liver dysfunction and is defined as a spectrum of neuropsychiatric abnormalities, after exclusion of brain disease. Further, increasing prevalence of liver disease and high mortality rate, such factors are driving the Global Hepatic Encephalopathy market.

According to AMA, the Global Hepatic Encephalopathy market is expected to see growth rate of 6.5%

The Global Hepatic Encephalopathy market is moderately fragmented with several players. The market is exhibiting a moderate growth mostly due to an upsurge in the patient population suffering from the cirrhosis disease. Different types of therapeutic drugs in the pipeline for the treatment of HE. Several clinical trial drug treatment for HE are being carried out by researchers. For instance, KLS-13019 is a drug developed by Kanna Life Sciences and is currently under the pre-clinical phase. It is a cannabinoid, which acts on cannabinoid receptors in cells that alter the neurotransmitter release inside the brain.

ASKA Pharmaceutical Co., Ltd.(Japan), Cosmo Pharmaceuticals N.V. (Ireland), Lupin Limited (India), Kaleido Biosciences (United States), Kannalife Sciences, Inc. (United States), Bausch Health Companies Inc. (Canada), Ferring Pharmaceuticals Inc. (Switzerland), Mallinckrodt Pharmaceuticals (United Kingdom), Umecrine Cognition AB (Sweden) and Norgine B.V. (Netherlands) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Hepatic Encephalopathy market , by Application (Acute Liver Failure, Portal Systemic Bypass Without Liver Disease and Liver Cirrhosis) and Region with country level break-up.

On the basis of geography, the market of Hepatic Encephalopathy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In 2017, Umecrine Cognition company is developing a therapy that represents a new target class for several major central nervous system (CNS)-related disorders. The lead compound GR3027 is presently in clinical development for HE. The company plans to demonstrate Phase II data of GR3027 for the treatment of HE in 2020.
January 2018, Rebiotix Inc.(Ferring Pharmaceuticals Inc.) is developing a drug i.e. RBX2477 that can be administered orally for HE. The drug is presently under Phase I clinical trial. It is an antibiotic that reduces the production of ammonia by inhibiting the growth of ammonia-producing colonic bacteria.


Market Trend
  • Rising Awareness Program on Liver Disease and Liver Cancer
  • The Emergence of Novel Treatment Target for HE

Market Drivers
  • Increasing Number of Products in the Pipeline for the Treatment of HE
  • Growing Prevalence of Liver Diseases
  • Increased Mortality Rate & Hospitalizations

Opportunities
  • Rising Number of Clinical Trials on the Effective Drug Treatment for HE

Restraints
  • Cost Factor Associated in Treatment of Hepatic Encephalopathy

Challenges
  • Delay and Inaccurate Diagnosis for HE is Posing a Challenge for the Market


Key Target Audience
Hepatic Encephalopathy Drug Manufacturers, Pharmaceutical Companies, Government & Regulatory Bodies, Industry Associations, Marketing firms, Research Organizations and Others

Report Objectives / Segmentation Covered

By Application
  • Acute Liver Failure
  • Portal Systemic Bypass Without Liver Disease
  • Liver Cirrhosis
By End users
  • Hospitals
  • Research Institutes
  • Clinics & Surgical centers
  • Others

By Type
  • Type A
  • Type B
  • Type C

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Disease Severity
  • Covert Hepatic Encephalopathy (CHE)
  • Overt Hepatic Encephalopathy (OHE)

By Drug Class
  • Antibiotics
  • Laxatives
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Products in the Pipeline for the Treatment of HE
      • 3.2.2. Growing Prevalence of Liver Diseases
      • 3.2.3. Increased Mortality Rate & Hospitalizations
    • 3.3. Market Challenges
      • 3.3.1. Delay and Inaccurate Diagnosis for HE is Posing a Challenge for the Market
    • 3.4. Market Trends
      • 3.4.1. Rising Awareness Program on Liver Disease and Liver Cancer
      • 3.4.2. The Emergence of Novel Treatment Target for HE
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hepatic Encephalopathy, by Application, End users, Type, Distribution Channel, Disease Severity, Drug Class and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Hepatic Encephalopathy (Value)
      • 5.2.1. Global Hepatic Encephalopathy by: Type (Value)
        • 5.2.1.1. Type A
        • 5.2.1.2. Type B
        • 5.2.1.3. Type C
      • 5.2.2. Global Hepatic Encephalopathy by: Application (Value)
        • 5.2.2.1. Acute Liver Failure
        • 5.2.2.2. Portal Systemic Bypass Without Liver Disease
        • 5.2.2.3. Liver Cirrhosis
      • 5.2.3. Global Hepatic Encephalopathy by: End users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Research Institutes
        • 5.2.3.3. Clinics & Surgical centers
        • 5.2.3.4. Others
      • 5.2.4. Global Hepatic Encephalopathy by: Type (Value)
        • 5.2.4.1. Type A
        • 5.2.4.2. Type B
        • 5.2.4.3. Type C
      • 5.2.5. Global Hepatic Encephalopathy by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Retail Pharmacies
        • 5.2.5.3. Online Pharmacies
      • 5.2.6. Global Hepatic Encephalopathy by: Disease Severity (Value)
        • 5.2.6.1. Covert Hepatic Encephalopathy (CHE)
        • 5.2.6.2. Overt Hepatic Encephalopathy (OHE)
      • 5.2.7. Global Hepatic Encephalopathy by: Drug Class (Value)
        • 5.2.7.1. Antibiotics
        • 5.2.7.2. Laxatives
        • 5.2.7.3. Others
      • 5.2.8. Global Hepatic Encephalopathy Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Hepatic Encephalopathy (Volume)
      • 5.3.1. Global Hepatic Encephalopathy by: Type (Volume)
        • 5.3.1.1. Type A
        • 5.3.1.2. Type B
        • 5.3.1.3. Type C
      • 5.3.2. Global Hepatic Encephalopathy by: Application (Volume)
        • 5.3.2.1. Acute Liver Failure
        • 5.3.2.2. Portal Systemic Bypass Without Liver Disease
        • 5.3.2.3. Liver Cirrhosis
      • 5.3.3. Global Hepatic Encephalopathy by: End users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Research Institutes
        • 5.3.3.3. Clinics & Surgical centers
        • 5.3.3.4. Others
      • 5.3.4. Global Hepatic Encephalopathy by: Type (Volume)
        • 5.3.4.1. Type A
        • 5.3.4.2. Type B
        • 5.3.4.3. Type C
      • 5.3.5. Global Hepatic Encephalopathy by: Distribution Channel (Volume)
        • 5.3.5.1. Hospital Pharmacies
        • 5.3.5.2. Retail Pharmacies
        • 5.3.5.3. Online Pharmacies
      • 5.3.6. Global Hepatic Encephalopathy by: Disease Severity (Volume)
        • 5.3.6.1. Covert Hepatic Encephalopathy (CHE)
        • 5.3.6.2. Overt Hepatic Encephalopathy (OHE)
      • 5.3.7. Global Hepatic Encephalopathy by: Drug Class (Volume)
        • 5.3.7.1. Antibiotics
        • 5.3.7.2. Laxatives
        • 5.3.7.3. Others
      • 5.3.8. Global Hepatic Encephalopathy Region
        • 5.3.8.1. South America
          • 5.3.8.1.1. Brazil
          • 5.3.8.1.2. Argentina
          • 5.3.8.1.3. Rest of South America
        • 5.3.8.2. Asia Pacific
          • 5.3.8.2.1. China
          • 5.3.8.2.2. Japan
          • 5.3.8.2.3. India
          • 5.3.8.2.4. South Korea
          • 5.3.8.2.5. Taiwan
          • 5.3.8.2.6. Australia
          • 5.3.8.2.7. Rest of Asia-Pacific
        • 5.3.8.3. Europe
          • 5.3.8.3.1. Germany
          • 5.3.8.3.2. France
          • 5.3.8.3.3. Italy
          • 5.3.8.3.4. United Kingdom
          • 5.3.8.3.5. Netherlands
          • 5.3.8.3.6. Rest of Europe
        • 5.3.8.4. MEA
          • 5.3.8.4.1. Middle East
          • 5.3.8.4.2. Africa
        • 5.3.8.5. North America
          • 5.3.8.5.1. United States
          • 5.3.8.5.2. Canada
          • 5.3.8.5.3. Mexico
    • 5.4. Global Hepatic Encephalopathy (Price)
  • 6. Hepatic Encephalopathy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ASKA Pharmaceutical Co., Ltd.(Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cosmo Pharmaceuticals N.V. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lupin Limited (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Kaleido Biosciences (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kannalife Sciences, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bausch Health Companies Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ferring Pharmaceuticals Inc. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mallinckrodt Pharmaceuticals (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Umecrine Cognition AB (Sweden)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Norgine B.V. (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hepatic Encephalopathy Sale, by Application, End users, Type, Distribution Channel, Disease Severity, Drug Class and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Hepatic Encephalopathy (Value)
      • 7.2.1. Global Hepatic Encephalopathy by: Type (Value)
        • 7.2.1.1. Type A
        • 7.2.1.2. Type B
        • 7.2.1.3. Type C
      • 7.2.2. Global Hepatic Encephalopathy by: Application (Value)
        • 7.2.2.1. Acute Liver Failure
        • 7.2.2.2. Portal Systemic Bypass Without Liver Disease
        • 7.2.2.3. Liver Cirrhosis
      • 7.2.3. Global Hepatic Encephalopathy by: End users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Research Institutes
        • 7.2.3.3. Clinics & Surgical centers
        • 7.2.3.4. Others
      • 7.2.4. Global Hepatic Encephalopathy by: Type (Value)
        • 7.2.4.1. Type A
        • 7.2.4.2. Type B
        • 7.2.4.3. Type C
      • 7.2.5. Global Hepatic Encephalopathy by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Retail Pharmacies
        • 7.2.5.3. Online Pharmacies
      • 7.2.6. Global Hepatic Encephalopathy by: Disease Severity (Value)
        • 7.2.6.1. Covert Hepatic Encephalopathy (CHE)
        • 7.2.6.2. Overt Hepatic Encephalopathy (OHE)
      • 7.2.7. Global Hepatic Encephalopathy by: Drug Class (Value)
        • 7.2.7.1. Antibiotics
        • 7.2.7.2. Laxatives
        • 7.2.7.3. Others
      • 7.2.8. Global Hepatic Encephalopathy Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Hepatic Encephalopathy (Volume)
      • 7.3.1. Global Hepatic Encephalopathy by: Type (Volume)
        • 7.3.1.1. Type A
        • 7.3.1.2. Type B
        • 7.3.1.3. Type C
      • 7.3.2. Global Hepatic Encephalopathy by: Application (Volume)
        • 7.3.2.1. Acute Liver Failure
        • 7.3.2.2. Portal Systemic Bypass Without Liver Disease
        • 7.3.2.3. Liver Cirrhosis
      • 7.3.3. Global Hepatic Encephalopathy by: End users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Research Institutes
        • 7.3.3.3. Clinics & Surgical centers
        • 7.3.3.4. Others
      • 7.3.4. Global Hepatic Encephalopathy by: Type (Volume)
        • 7.3.4.1. Type A
        • 7.3.4.2. Type B
        • 7.3.4.3. Type C
      • 7.3.5. Global Hepatic Encephalopathy by: Distribution Channel (Volume)
        • 7.3.5.1. Hospital Pharmacies
        • 7.3.5.2. Retail Pharmacies
        • 7.3.5.3. Online Pharmacies
      • 7.3.6. Global Hepatic Encephalopathy by: Disease Severity (Volume)
        • 7.3.6.1. Covert Hepatic Encephalopathy (CHE)
        • 7.3.6.2. Overt Hepatic Encephalopathy (OHE)
      • 7.3.7. Global Hepatic Encephalopathy by: Drug Class (Volume)
        • 7.3.7.1. Antibiotics
        • 7.3.7.2. Laxatives
        • 7.3.7.3. Others
      • 7.3.8. Global Hepatic Encephalopathy Region
        • 7.3.8.1. South America
          • 7.3.8.1.1. Brazil
          • 7.3.8.1.2. Argentina
          • 7.3.8.1.3. Rest of South America
        • 7.3.8.2. Asia Pacific
          • 7.3.8.2.1. China
          • 7.3.8.2.2. Japan
          • 7.3.8.2.3. India
          • 7.3.8.2.4. South Korea
          • 7.3.8.2.5. Taiwan
          • 7.3.8.2.6. Australia
          • 7.3.8.2.7. Rest of Asia-Pacific
        • 7.3.8.3. Europe
          • 7.3.8.3.1. Germany
          • 7.3.8.3.2. France
          • 7.3.8.3.3. Italy
          • 7.3.8.3.4. United Kingdom
          • 7.3.8.3.5. Netherlands
          • 7.3.8.3.6. Rest of Europe
        • 7.3.8.4. MEA
          • 7.3.8.4.1. Middle East
          • 7.3.8.4.2. Africa
        • 7.3.8.5. North America
          • 7.3.8.5.1. United States
          • 7.3.8.5.2. Canada
          • 7.3.8.5.3. Mexico
    • 7.4. Global Hepatic Encephalopathy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hepatic Encephalopathy: by Type(USD Million)
  • Table 2. Hepatic Encephalopathy Type A , by Region USD Million (2016-2021)
  • Table 3. Hepatic Encephalopathy Type B , by Region USD Million (2016-2021)
  • Table 4. Hepatic Encephalopathy Type C , by Region USD Million (2016-2021)
  • Table 5. Hepatic Encephalopathy: by Application(USD Million)
  • Table 6. Hepatic Encephalopathy Acute Liver Failure , by Region USD Million (2016-2021)
  • Table 7. Hepatic Encephalopathy Portal Systemic Bypass Without Liver Disease , by Region USD Million (2016-2021)
  • Table 8. Hepatic Encephalopathy Liver Cirrhosis , by Region USD Million (2016-2021)
  • Table 9. Hepatic Encephalopathy: by End users(USD Million)
  • Table 10. Hepatic Encephalopathy Hospitals , by Region USD Million (2016-2021)
  • Table 11. Hepatic Encephalopathy Research Institutes , by Region USD Million (2016-2021)
  • Table 12. Hepatic Encephalopathy Clinics & Surgical centers , by Region USD Million (2016-2021)
  • Table 13. Hepatic Encephalopathy Others , by Region USD Million (2016-2021)
  • Table 14. Hepatic Encephalopathy: by Type(USD Million)
  • Table 15. Hepatic Encephalopathy Type A , by Region USD Million (2016-2021)
  • Table 16. Hepatic Encephalopathy Type B , by Region USD Million (2016-2021)
  • Table 17. Hepatic Encephalopathy Type C , by Region USD Million (2016-2021)
  • Table 18. Hepatic Encephalopathy: by Distribution Channel(USD Million)
  • Table 19. Hepatic Encephalopathy Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 20. Hepatic Encephalopathy Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 21. Hepatic Encephalopathy Online Pharmacies , by Region USD Million (2016-2021)
  • Table 22. Hepatic Encephalopathy: by Disease Severity(USD Million)
  • Table 23. Hepatic Encephalopathy Covert Hepatic Encephalopathy (CHE) , by Region USD Million (2016-2021)
  • Table 24. Hepatic Encephalopathy Overt Hepatic Encephalopathy (OHE) , by Region USD Million (2016-2021)
  • Table 25. Hepatic Encephalopathy: by Drug Class(USD Million)
  • Table 26. Hepatic Encephalopathy Antibiotics , by Region USD Million (2016-2021)
  • Table 27. Hepatic Encephalopathy Laxatives , by Region USD Million (2016-2021)
  • Table 28. Hepatic Encephalopathy Others , by Region USD Million (2016-2021)
  • Table 29. South America Hepatic Encephalopathy, by Country USD Million (2016-2021)
  • Table 30. South America Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 31. South America Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 32. South America Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 33. South America Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 34. South America Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 35. South America Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 36. Brazil Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 37. Brazil Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 38. Brazil Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 39. Brazil Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 40. Brazil Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 41. Brazil Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 42. Argentina Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 43. Argentina Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 44. Argentina Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 45. Argentina Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 46. Argentina Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 47. Argentina Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 48. Rest of South America Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 49. Rest of South America Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 50. Rest of South America Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 51. Rest of South America Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 52. Rest of South America Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 53. Rest of South America Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 54. Asia Pacific Hepatic Encephalopathy, by Country USD Million (2016-2021)
  • Table 55. Asia Pacific Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 56. Asia Pacific Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 57. Asia Pacific Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 58. Asia Pacific Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 59. Asia Pacific Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 60. Asia Pacific Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 61. China Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 62. China Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 63. China Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 64. China Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 65. China Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 66. China Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 67. Japan Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 68. Japan Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 69. Japan Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 70. Japan Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 71. Japan Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 72. Japan Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 73. India Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 74. India Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 75. India Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 76. India Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 77. India Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 78. India Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 79. South Korea Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 80. South Korea Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 81. South Korea Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 82. South Korea Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 83. South Korea Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 84. South Korea Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 85. Taiwan Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 86. Taiwan Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 87. Taiwan Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 88. Taiwan Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 89. Taiwan Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 90. Taiwan Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 91. Australia Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 92. Australia Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 93. Australia Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 94. Australia Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 95. Australia Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 96. Australia Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 97. Rest of Asia-Pacific Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 98. Rest of Asia-Pacific Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 99. Rest of Asia-Pacific Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 100. Rest of Asia-Pacific Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 101. Rest of Asia-Pacific Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 102. Rest of Asia-Pacific Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 103. Europe Hepatic Encephalopathy, by Country USD Million (2016-2021)
  • Table 104. Europe Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 105. Europe Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 106. Europe Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 107. Europe Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 108. Europe Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 109. Europe Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 110. Germany Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 111. Germany Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 112. Germany Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 113. Germany Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 114. Germany Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 115. Germany Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 116. France Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 117. France Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 118. France Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 119. France Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 120. France Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 121. France Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 122. Italy Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 123. Italy Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 124. Italy Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 125. Italy Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 126. Italy Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 127. Italy Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 128. United Kingdom Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 129. United Kingdom Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 130. United Kingdom Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 131. United Kingdom Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 132. United Kingdom Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 133. United Kingdom Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 134. Netherlands Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 135. Netherlands Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 136. Netherlands Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 137. Netherlands Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 138. Netherlands Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 139. Netherlands Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 140. Rest of Europe Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 141. Rest of Europe Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 142. Rest of Europe Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 143. Rest of Europe Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 144. Rest of Europe Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 145. Rest of Europe Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 146. MEA Hepatic Encephalopathy, by Country USD Million (2016-2021)
  • Table 147. MEA Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 148. MEA Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 149. MEA Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 150. MEA Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 151. MEA Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 152. MEA Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 153. Middle East Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 154. Middle East Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 155. Middle East Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 156. Middle East Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 157. Middle East Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 158. Middle East Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 159. Africa Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 160. Africa Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 161. Africa Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 162. Africa Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 163. Africa Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 164. Africa Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 165. North America Hepatic Encephalopathy, by Country USD Million (2016-2021)
  • Table 166. North America Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 167. North America Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 168. North America Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 169. North America Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 170. North America Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 171. North America Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 172. United States Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 173. United States Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 174. United States Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 175. United States Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 176. United States Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 177. United States Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 178. Canada Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 179. Canada Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 180. Canada Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 181. Canada Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 182. Canada Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 183. Canada Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 184. Mexico Hepatic Encephalopathy, by Application USD Million (2016-2021)
  • Table 185. Mexico Hepatic Encephalopathy, by End users USD Million (2016-2021)
  • Table 186. Mexico Hepatic Encephalopathy, by Type USD Million (2016-2021)
  • Table 187. Mexico Hepatic Encephalopathy, by Distribution Channel USD Million (2016-2021)
  • Table 188. Mexico Hepatic Encephalopathy, by Disease Severity USD Million (2016-2021)
  • Table 189. Mexico Hepatic Encephalopathy, by Drug Class USD Million (2016-2021)
  • Table 190. Hepatic Encephalopathy Sales: by Type(K Units)
  • Table 191. Hepatic Encephalopathy Sales Type A , by Region K Units (2016-2021)
  • Table 192. Hepatic Encephalopathy Sales Type B , by Region K Units (2016-2021)
  • Table 193. Hepatic Encephalopathy Sales Type C , by Region K Units (2016-2021)
  • Table 194. Hepatic Encephalopathy Sales: by Application(K Units)
  • Table 195. Hepatic Encephalopathy Sales Acute Liver Failure , by Region K Units (2016-2021)
  • Table 196. Hepatic Encephalopathy Sales Portal Systemic Bypass Without Liver Disease , by Region K Units (2016-2021)
  • Table 197. Hepatic Encephalopathy Sales Liver Cirrhosis , by Region K Units (2016-2021)
  • Table 198. Hepatic Encephalopathy Sales: by End users(K Units)
  • Table 199. Hepatic Encephalopathy Sales Hospitals , by Region K Units (2016-2021)
  • Table 200. Hepatic Encephalopathy Sales Research Institutes , by Region K Units (2016-2021)
  • Table 201. Hepatic Encephalopathy Sales Clinics & Surgical centers , by Region K Units (2016-2021)
  • Table 202. Hepatic Encephalopathy Sales Others , by Region K Units (2016-2021)
  • Table 203. Hepatic Encephalopathy Sales: by Type(K Units)
  • Table 204. Hepatic Encephalopathy Sales Type A , by Region K Units (2016-2021)
  • Table 205. Hepatic Encephalopathy Sales Type B , by Region K Units (2016-2021)
  • Table 206. Hepatic Encephalopathy Sales Type C , by Region K Units (2016-2021)
  • Table 207. Hepatic Encephalopathy Sales: by Distribution Channel(K Units)
  • Table 208. Hepatic Encephalopathy Sales Hospital Pharmacies , by Region K Units (2016-2021)
  • Table 209. Hepatic Encephalopathy Sales Retail Pharmacies , by Region K Units (2016-2021)
  • Table 210. Hepatic Encephalopathy Sales Online Pharmacies , by Region K Units (2016-2021)
  • Table 211. Hepatic Encephalopathy Sales: by Disease Severity(K Units)
  • Table 212. Hepatic Encephalopathy Sales Covert Hepatic Encephalopathy (CHE) , by Region K Units (2016-2021)
  • Table 213. Hepatic Encephalopathy Sales Overt Hepatic Encephalopathy (OHE) , by Region K Units (2016-2021)
  • Table 214. Hepatic Encephalopathy Sales: by Drug Class(K Units)
  • Table 215. Hepatic Encephalopathy Sales Antibiotics , by Region K Units (2016-2021)
  • Table 216. Hepatic Encephalopathy Sales Laxatives , by Region K Units (2016-2021)
  • Table 217. Hepatic Encephalopathy Sales Others , by Region K Units (2016-2021)
  • Table 218. South America Hepatic Encephalopathy Sales, by Country K Units (2016-2021)
  • Table 219. South America Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 220. South America Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 221. South America Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 222. South America Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 223. South America Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 224. South America Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 225. Brazil Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 226. Brazil Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 227. Brazil Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 228. Brazil Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 229. Brazil Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 230. Brazil Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 231. Argentina Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 232. Argentina Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 233. Argentina Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 234. Argentina Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 235. Argentina Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 236. Argentina Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 237. Rest of South America Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 238. Rest of South America Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 239. Rest of South America Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 240. Rest of South America Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 241. Rest of South America Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 242. Rest of South America Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 243. Asia Pacific Hepatic Encephalopathy Sales, by Country K Units (2016-2021)
  • Table 244. Asia Pacific Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 245. Asia Pacific Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 246. Asia Pacific Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 247. Asia Pacific Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 248. Asia Pacific Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 249. Asia Pacific Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 250. China Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 251. China Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 252. China Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 253. China Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 254. China Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 255. China Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 256. Japan Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 257. Japan Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 258. Japan Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 259. Japan Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 260. Japan Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 261. Japan Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 262. India Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 263. India Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 264. India Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 265. India Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 266. India Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 267. India Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 268. South Korea Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 269. South Korea Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 270. South Korea Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 271. South Korea Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 272. South Korea Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 273. South Korea Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 274. Taiwan Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 275. Taiwan Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 276. Taiwan Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 277. Taiwan Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 278. Taiwan Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 279. Taiwan Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 280. Australia Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 281. Australia Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 282. Australia Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 283. Australia Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 284. Australia Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 285. Australia Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 286. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 287. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 288. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 289. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 290. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 291. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 292. Europe Hepatic Encephalopathy Sales, by Country K Units (2016-2021)
  • Table 293. Europe Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 294. Europe Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 295. Europe Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 296. Europe Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 297. Europe Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 298. Europe Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 299. Germany Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 300. Germany Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 301. Germany Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 302. Germany Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 303. Germany Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 304. Germany Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 305. France Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 306. France Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 307. France Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 308. France Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 309. France Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 310. France Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 311. Italy Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 312. Italy Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 313. Italy Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 314. Italy Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 315. Italy Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 316. Italy Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 317. United Kingdom Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 318. United Kingdom Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 319. United Kingdom Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 320. United Kingdom Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 321. United Kingdom Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 322. United Kingdom Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 323. Netherlands Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 324. Netherlands Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 325. Netherlands Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 326. Netherlands Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 327. Netherlands Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 328. Netherlands Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 329. Rest of Europe Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 330. Rest of Europe Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 331. Rest of Europe Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 332. Rest of Europe Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 333. Rest of Europe Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 334. Rest of Europe Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 335. MEA Hepatic Encephalopathy Sales, by Country K Units (2016-2021)
  • Table 336. MEA Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 337. MEA Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 338. MEA Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 339. MEA Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 340. MEA Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 341. MEA Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 342. Middle East Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 343. Middle East Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 344. Middle East Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 345. Middle East Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 346. Middle East Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 347. Middle East Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 348. Africa Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 349. Africa Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 350. Africa Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 351. Africa Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 352. Africa Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 353. Africa Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 354. North America Hepatic Encephalopathy Sales, by Country K Units (2016-2021)
  • Table 355. North America Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 356. North America Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 357. North America Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 358. North America Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 359. North America Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 360. North America Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 361. United States Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 362. United States Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 363. United States Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 364. United States Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 365. United States Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 366. United States Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 367. Canada Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 368. Canada Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 369. Canada Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 370. Canada Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 371. Canada Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 372. Canada Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 373. Mexico Hepatic Encephalopathy Sales, by Application K Units (2016-2021)
  • Table 374. Mexico Hepatic Encephalopathy Sales, by End users K Units (2016-2021)
  • Table 375. Mexico Hepatic Encephalopathy Sales, by Type K Units (2016-2021)
  • Table 376. Mexico Hepatic Encephalopathy Sales, by Distribution Channel K Units (2016-2021)
  • Table 377. Mexico Hepatic Encephalopathy Sales, by Disease Severity K Units (2016-2021)
  • Table 378. Mexico Hepatic Encephalopathy Sales, by Drug Class K Units (2016-2021)
  • Table 379. Company Basic Information, Sales Area and Its Competitors
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Company Basic Information, Sales Area and Its Competitors
  • Table 383. Company Basic Information, Sales Area and Its Competitors
  • Table 384. Company Basic Information, Sales Area and Its Competitors
  • Table 385. Company Basic Information, Sales Area and Its Competitors
  • Table 386. Company Basic Information, Sales Area and Its Competitors
  • Table 387. Company Basic Information, Sales Area and Its Competitors
  • Table 388. Company Basic Information, Sales Area and Its Competitors
  • Table 389. Hepatic Encephalopathy: by Type(USD Million)
  • Table 390. Hepatic Encephalopathy Type A , by Region USD Million (2022-2027)
  • Table 391. Hepatic Encephalopathy Type B , by Region USD Million (2022-2027)
  • Table 392. Hepatic Encephalopathy Type C , by Region USD Million (2022-2027)
  • Table 393. Hepatic Encephalopathy: by Application(USD Million)
  • Table 394. Hepatic Encephalopathy Acute Liver Failure , by Region USD Million (2022-2027)
  • Table 395. Hepatic Encephalopathy Portal Systemic Bypass Without Liver Disease , by Region USD Million (2022-2027)
  • Table 396. Hepatic Encephalopathy Liver Cirrhosis , by Region USD Million (2022-2027)
  • Table 397. Hepatic Encephalopathy: by End users(USD Million)
  • Table 398. Hepatic Encephalopathy Hospitals , by Region USD Million (2022-2027)
  • Table 399. Hepatic Encephalopathy Research Institutes , by Region USD Million (2022-2027)
  • Table 400. Hepatic Encephalopathy Clinics & Surgical centers , by Region USD Million (2022-2027)
  • Table 401. Hepatic Encephalopathy Others , by Region USD Million (2022-2027)
  • Table 402. Hepatic Encephalopathy: by Type(USD Million)
  • Table 403. Hepatic Encephalopathy Type A , by Region USD Million (2022-2027)
  • Table 404. Hepatic Encephalopathy Type B , by Region USD Million (2022-2027)
  • Table 405. Hepatic Encephalopathy Type C , by Region USD Million (2022-2027)
  • Table 406. Hepatic Encephalopathy: by Distribution Channel(USD Million)
  • Table 407. Hepatic Encephalopathy Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 408. Hepatic Encephalopathy Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 409. Hepatic Encephalopathy Online Pharmacies , by Region USD Million (2022-2027)
  • Table 410. Hepatic Encephalopathy: by Disease Severity(USD Million)
  • Table 411. Hepatic Encephalopathy Covert Hepatic Encephalopathy (CHE) , by Region USD Million (2022-2027)
  • Table 412. Hepatic Encephalopathy Overt Hepatic Encephalopathy (OHE) , by Region USD Million (2022-2027)
  • Table 413. Hepatic Encephalopathy: by Drug Class(USD Million)
  • Table 414. Hepatic Encephalopathy Antibiotics , by Region USD Million (2022-2027)
  • Table 415. Hepatic Encephalopathy Laxatives , by Region USD Million (2022-2027)
  • Table 416. Hepatic Encephalopathy Others , by Region USD Million (2022-2027)
  • Table 417. South America Hepatic Encephalopathy, by Country USD Million (2022-2027)
  • Table 418. South America Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 419. South America Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 420. South America Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 421. South America Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 422. South America Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 423. South America Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 424. Brazil Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 425. Brazil Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 426. Brazil Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 427. Brazil Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 428. Brazil Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 429. Brazil Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 430. Argentina Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 431. Argentina Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 432. Argentina Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 433. Argentina Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 434. Argentina Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 435. Argentina Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 436. Rest of South America Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 437. Rest of South America Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 438. Rest of South America Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 439. Rest of South America Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 440. Rest of South America Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 441. Rest of South America Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 442. Asia Pacific Hepatic Encephalopathy, by Country USD Million (2022-2027)
  • Table 443. Asia Pacific Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 444. Asia Pacific Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 445. Asia Pacific Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 446. Asia Pacific Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 447. Asia Pacific Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 448. Asia Pacific Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 449. China Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 450. China Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 451. China Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 452. China Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 453. China Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 454. China Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 455. Japan Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 456. Japan Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 457. Japan Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 458. Japan Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 459. Japan Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 460. Japan Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 461. India Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 462. India Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 463. India Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 464. India Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 465. India Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 466. India Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 467. South Korea Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 468. South Korea Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 469. South Korea Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 470. South Korea Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 471. South Korea Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 472. South Korea Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 473. Taiwan Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 474. Taiwan Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 475. Taiwan Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 476. Taiwan Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 477. Taiwan Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 478. Taiwan Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 479. Australia Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 480. Australia Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 481. Australia Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 482. Australia Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 483. Australia Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 484. Australia Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 485. Rest of Asia-Pacific Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 486. Rest of Asia-Pacific Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 487. Rest of Asia-Pacific Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 488. Rest of Asia-Pacific Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 489. Rest of Asia-Pacific Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 490. Rest of Asia-Pacific Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 491. Europe Hepatic Encephalopathy, by Country USD Million (2022-2027)
  • Table 492. Europe Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 493. Europe Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 494. Europe Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 495. Europe Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 496. Europe Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 497. Europe Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 498. Germany Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 499. Germany Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 500. Germany Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 501. Germany Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 502. Germany Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 503. Germany Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 504. France Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 505. France Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 506. France Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 507. France Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 508. France Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 509. France Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 510. Italy Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 511. Italy Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 512. Italy Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 513. Italy Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 514. Italy Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 515. Italy Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 516. United Kingdom Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 517. United Kingdom Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 518. United Kingdom Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 519. United Kingdom Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 520. United Kingdom Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 521. United Kingdom Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 522. Netherlands Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 523. Netherlands Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 524. Netherlands Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 525. Netherlands Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 526. Netherlands Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 527. Netherlands Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 528. Rest of Europe Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 529. Rest of Europe Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 530. Rest of Europe Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 531. Rest of Europe Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 532. Rest of Europe Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 533. Rest of Europe Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 534. MEA Hepatic Encephalopathy, by Country USD Million (2022-2027)
  • Table 535. MEA Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 536. MEA Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 537. MEA Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 538. MEA Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 539. MEA Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 540. MEA Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 541. Middle East Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 542. Middle East Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 543. Middle East Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 544. Middle East Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 545. Middle East Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 546. Middle East Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 547. Africa Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 548. Africa Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 549. Africa Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 550. Africa Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 551. Africa Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 552. Africa Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 553. North America Hepatic Encephalopathy, by Country USD Million (2022-2027)
  • Table 554. North America Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 555. North America Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 556. North America Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 557. North America Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 558. North America Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 559. North America Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 560. United States Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 561. United States Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 562. United States Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 563. United States Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 564. United States Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 565. United States Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 566. Canada Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 567. Canada Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 568. Canada Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 569. Canada Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 570. Canada Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 571. Canada Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 572. Mexico Hepatic Encephalopathy, by Application USD Million (2022-2027)
  • Table 573. Mexico Hepatic Encephalopathy, by End users USD Million (2022-2027)
  • Table 574. Mexico Hepatic Encephalopathy, by Type USD Million (2022-2027)
  • Table 575. Mexico Hepatic Encephalopathy, by Distribution Channel USD Million (2022-2027)
  • Table 576. Mexico Hepatic Encephalopathy, by Disease Severity USD Million (2022-2027)
  • Table 577. Mexico Hepatic Encephalopathy, by Drug Class USD Million (2022-2027)
  • Table 578. Hepatic Encephalopathy Sales: by Type(K Units)
  • Table 579. Hepatic Encephalopathy Sales Type A , by Region K Units (2022-2027)
  • Table 580. Hepatic Encephalopathy Sales Type B , by Region K Units (2022-2027)
  • Table 581. Hepatic Encephalopathy Sales Type C , by Region K Units (2022-2027)
  • Table 582. Hepatic Encephalopathy Sales: by Application(K Units)
  • Table 583. Hepatic Encephalopathy Sales Acute Liver Failure , by Region K Units (2022-2027)
  • Table 584. Hepatic Encephalopathy Sales Portal Systemic Bypass Without Liver Disease , by Region K Units (2022-2027)
  • Table 585. Hepatic Encephalopathy Sales Liver Cirrhosis , by Region K Units (2022-2027)
  • Table 586. Hepatic Encephalopathy Sales: by End users(K Units)
  • Table 587. Hepatic Encephalopathy Sales Hospitals , by Region K Units (2022-2027)
  • Table 588. Hepatic Encephalopathy Sales Research Institutes , by Region K Units (2022-2027)
  • Table 589. Hepatic Encephalopathy Sales Clinics & Surgical centers , by Region K Units (2022-2027)
  • Table 590. Hepatic Encephalopathy Sales Others , by Region K Units (2022-2027)
  • Table 591. Hepatic Encephalopathy Sales: by Type(K Units)
  • Table 592. Hepatic Encephalopathy Sales Type A , by Region K Units (2022-2027)
  • Table 593. Hepatic Encephalopathy Sales Type B , by Region K Units (2022-2027)
  • Table 594. Hepatic Encephalopathy Sales Type C , by Region K Units (2022-2027)
  • Table 595. Hepatic Encephalopathy Sales: by Distribution Channel(K Units)
  • Table 596. Hepatic Encephalopathy Sales Hospital Pharmacies , by Region K Units (2022-2027)
  • Table 597. Hepatic Encephalopathy Sales Retail Pharmacies , by Region K Units (2022-2027)
  • Table 598. Hepatic Encephalopathy Sales Online Pharmacies , by Region K Units (2022-2027)
  • Table 599. Hepatic Encephalopathy Sales: by Disease Severity(K Units)
  • Table 600. Hepatic Encephalopathy Sales Covert Hepatic Encephalopathy (CHE) , by Region K Units (2022-2027)
  • Table 601. Hepatic Encephalopathy Sales Overt Hepatic Encephalopathy (OHE) , by Region K Units (2022-2027)
  • Table 602. Hepatic Encephalopathy Sales: by Drug Class(K Units)
  • Table 603. Hepatic Encephalopathy Sales Antibiotics , by Region K Units (2022-2027)
  • Table 604. Hepatic Encephalopathy Sales Laxatives , by Region K Units (2022-2027)
  • Table 605. Hepatic Encephalopathy Sales Others , by Region K Units (2022-2027)
  • Table 606. South America Hepatic Encephalopathy Sales, by Country K Units (2022-2027)
  • Table 607. South America Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 608. South America Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 609. South America Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 610. South America Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 611. South America Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 612. South America Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 613. Brazil Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 614. Brazil Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 615. Brazil Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 616. Brazil Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 617. Brazil Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 618. Brazil Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 619. Argentina Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 620. Argentina Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 621. Argentina Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 622. Argentina Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 623. Argentina Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 624. Argentina Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 625. Rest of South America Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 626. Rest of South America Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 627. Rest of South America Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 628. Rest of South America Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 629. Rest of South America Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 630. Rest of South America Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 631. Asia Pacific Hepatic Encephalopathy Sales, by Country K Units (2022-2027)
  • Table 632. Asia Pacific Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 633. Asia Pacific Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 634. Asia Pacific Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 635. Asia Pacific Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 636. Asia Pacific Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 637. Asia Pacific Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 638. China Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 639. China Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 640. China Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 641. China Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 642. China Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 643. China Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 644. Japan Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 645. Japan Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 646. Japan Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 647. Japan Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 648. Japan Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 649. Japan Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 650. India Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 651. India Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 652. India Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 653. India Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 654. India Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 655. India Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 656. South Korea Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 657. South Korea Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 658. South Korea Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 659. South Korea Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 660. South Korea Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 661. South Korea Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 662. Taiwan Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 663. Taiwan Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 664. Taiwan Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 665. Taiwan Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 666. Taiwan Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 667. Taiwan Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 668. Australia Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 669. Australia Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 670. Australia Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 671. Australia Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 672. Australia Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 673. Australia Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 674. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 675. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 676. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 677. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 678. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 679. Rest of Asia-Pacific Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 680. Europe Hepatic Encephalopathy Sales, by Country K Units (2022-2027)
  • Table 681. Europe Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 682. Europe Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 683. Europe Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 684. Europe Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 685. Europe Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 686. Europe Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 687. Germany Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 688. Germany Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 689. Germany Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 690. Germany Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 691. Germany Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 692. Germany Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 693. France Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 694. France Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 695. France Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 696. France Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 697. France Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 698. France Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 699. Italy Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 700. Italy Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 701. Italy Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
  • Table 702. Italy Hepatic Encephalopathy Sales, by Distribution Channel K Units (2022-2027)
  • Table 703. Italy Hepatic Encephalopathy Sales, by Disease Severity K Units (2022-2027)
  • Table 704. Italy Hepatic Encephalopathy Sales, by Drug Class K Units (2022-2027)
  • Table 705. United Kingdom Hepatic Encephalopathy Sales, by Application K Units (2022-2027)
  • Table 706. United Kingdom Hepatic Encephalopathy Sales, by End users K Units (2022-2027)
  • Table 707. United Kingdom Hepatic Encephalopathy Sales, by Type K Units (2022-2027)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hepatic Encephalopathy: by Type USD Million (2016-2021)
  • Figure 5. Global Hepatic Encephalopathy: by Application USD Million (2016-2021)
  • Figure 6. Global Hepatic Encephalopathy: by End users USD Million (2016-2021)
  • Figure 7. Global Hepatic Encephalopathy: by Type USD Million (2016-2021)
  • Figure 8. Global Hepatic Encephalopathy: by Distribution Channel USD Million (2016-2021)
  • Figure 9. Global Hepatic Encephalopathy: by Disease Severity USD Million (2016-2021)
  • Figure 10. Global Hepatic Encephalopathy: by Drug Class USD Million (2016-2021)
  • Figure 11. South America Hepatic Encephalopathy Share (%), by Country
  • Figure 12. Asia Pacific Hepatic Encephalopathy Share (%), by Country
  • Figure 13. Europe Hepatic Encephalopathy Share (%), by Country
  • Figure 14. MEA Hepatic Encephalopathy Share (%), by Country
  • Figure 15. North America Hepatic Encephalopathy Share (%), by Country
  • Figure 16. Global Hepatic Encephalopathy: by Type K Units (2016-2021)
  • Figure 17. Global Hepatic Encephalopathy: by Application K Units (2016-2021)
  • Figure 18. Global Hepatic Encephalopathy: by End users K Units (2016-2021)
  • Figure 19. Global Hepatic Encephalopathy: by Type K Units (2016-2021)
  • Figure 20. Global Hepatic Encephalopathy: by Distribution Channel K Units (2016-2021)
  • Figure 21. Global Hepatic Encephalopathy: by Disease Severity K Units (2016-2021)
  • Figure 22. Global Hepatic Encephalopathy: by Drug Class K Units (2016-2021)
  • Figure 23. South America Hepatic Encephalopathy Share (%), by Country
  • Figure 24. Asia Pacific Hepatic Encephalopathy Share (%), by Country
  • Figure 25. Europe Hepatic Encephalopathy Share (%), by Country
  • Figure 26. MEA Hepatic Encephalopathy Share (%), by Country
  • Figure 27. North America Hepatic Encephalopathy Share (%), by Country
  • Figure 28. Global Hepatic Encephalopathy share by Players 2021 (%)
  • Figure 29. Global Hepatic Encephalopathy share by Players (Top 3) 2021(%)
  • Figure 30. Global Hepatic Encephalopathy share by Players (Top 5) 2021(%)
  • Figure 31. BCG Matrix for key Companies
  • Figure 32. ASKA Pharmaceutical Co., Ltd.(Japan) Revenue, Net Income and Gross profit
  • Figure 33. ASKA Pharmaceutical Co., Ltd.(Japan) Revenue: by Geography 2021
  • Figure 34. Cosmo Pharmaceuticals N.V. (Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Cosmo Pharmaceuticals N.V. (Ireland) Revenue: by Geography 2021
  • Figure 36. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Lupin Limited (India) Revenue: by Geography 2021
  • Figure 38. Kaleido Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 39. Kaleido Biosciences (United States) Revenue: by Geography 2021
  • Figure 40. Kannalife Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Kannalife Sciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 42. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 43. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2021
  • Figure 44. Ferring Pharmaceuticals Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 45. Ferring Pharmaceuticals Inc. (Switzerland) Revenue: by Geography 2021
  • Figure 46. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 47. Mallinckrodt Pharmaceuticals (United Kingdom) Revenue: by Geography 2021
  • Figure 48. Umecrine Cognition AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 49. Umecrine Cognition AB (Sweden) Revenue: by Geography 2021
  • Figure 50. Norgine B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 51. Norgine B.V. (Netherlands) Revenue: by Geography 2021
  • Figure 52. Global Hepatic Encephalopathy: by Type USD Million (2022-2027)
  • Figure 53. Global Hepatic Encephalopathy: by Application USD Million (2022-2027)
  • Figure 54. Global Hepatic Encephalopathy: by End users USD Million (2022-2027)
  • Figure 55. Global Hepatic Encephalopathy: by Type USD Million (2022-2027)
  • Figure 56. Global Hepatic Encephalopathy: by Distribution Channel USD Million (2022-2027)
  • Figure 57. Global Hepatic Encephalopathy: by Disease Severity USD Million (2022-2027)
  • Figure 58. Global Hepatic Encephalopathy: by Drug Class USD Million (2022-2027)
  • Figure 59. South America Hepatic Encephalopathy Share (%), by Country
  • Figure 60. Asia Pacific Hepatic Encephalopathy Share (%), by Country
  • Figure 61. Europe Hepatic Encephalopathy Share (%), by Country
  • Figure 62. MEA Hepatic Encephalopathy Share (%), by Country
  • Figure 63. North America Hepatic Encephalopathy Share (%), by Country
  • Figure 64. Global Hepatic Encephalopathy: by Type K Units (2022-2027)
  • Figure 65. Global Hepatic Encephalopathy: by Application K Units (2022-2027)
  • Figure 66. Global Hepatic Encephalopathy: by End users K Units (2022-2027)
  • Figure 67. Global Hepatic Encephalopathy: by Type K Units (2022-2027)
  • Figure 68. Global Hepatic Encephalopathy: by Distribution Channel K Units (2022-2027)
  • Figure 69. Global Hepatic Encephalopathy: by Disease Severity K Units (2022-2027)
  • Figure 70. Global Hepatic Encephalopathy: by Drug Class K Units (2022-2027)
  • Figure 71. South America Hepatic Encephalopathy Share (%), by Country
  • Figure 72. Asia Pacific Hepatic Encephalopathy Share (%), by Country
  • Figure 73. Europe Hepatic Encephalopathy Share (%), by Country
  • Figure 74. MEA Hepatic Encephalopathy Share (%), by Country
  • Figure 75. North America Hepatic Encephalopathy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ASKA Pharmaceutical Co., Ltd.(Japan)
  • Cosmo Pharmaceuticals N.V. (Ireland)
  • Lupin Limited (India)
  • Kaleido Biosciences (United States)
  • Kannalife Sciences, Inc. (United States)
  • Bausch Health Companies Inc. (Canada)
  • Ferring Pharmaceuticals Inc. (Switzerland)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • Umecrine Cognition AB (Sweden)
  • Norgine B.V. (Netherlands)
Additional players considered in the study are as follows:
Salix Pharmaceuticals (United States) , Pfizer Inc. (United States) , Others
Select User Access Type

Key Highlights of Report


Jan 2024 225 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hepatic Encephalopathy Market Quantitative research analysis
Global Hepatic Encephalopathy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Hepatic Encephalopathy study can be customized to meet your requirements. The market size breakdown by type [], by end use application [Acute Liver Failure, Portal Systemic Bypass Without Liver Disease and Liver Cirrhosis].
The Hepatic Encephalopathy Market is gaining popularity and expected to see strong valuation by 2027.
According to AMA, the Global Hepatic Encephalopathy market is expected to see growth rate of 6.5%.

Know More About Global Hepatic Encephalopathy Market Report?

Have a Query? Click Here

Other Related Reports

Short Bowel Syndrome Comprehensive Study by Type (GLP-2, Growth Hormone, Glutamine, Others), Application (Hospitals, Clinics), Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)...
$ 3350
Epilepsy Drugs Comprehensive Study by Type (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)), Appl...
$ 3750
Next Generation Antibody Therapeutics Comprehensive Study by Type (Antibody Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Prote...
$ 3650
Microsclerotherapy Treatment Comprehensive Study by Type (Sclerosants (Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others), Micro-Needles, Graduated Compression Hosiery Supports, Othe...
$ 3450
Halitosis Treatment Comprehensive Study by Type (Pathological, Non-pathological), Application (Lungs, Liver, Respiratory, Systemic, Gastrointestinal, Others), Diagnostic Tests (Gas chromatography, Ha...
$ 3750
Circulating Tumor Cells (CTC) Comprehensive Study by Type (Ex-Vivo Positive Selection, In-Vivo Positive Selection, Negative Selection, Microchips & Single Spiral Micro Channel), Application (Tumorige...
$ 3450